BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

...cell death 1 TNFα - tumor necrosis factor α Hongjiang Li, Staff Writer Biosimilar trastuzumab (GB221) Biosimilar infliximab (GB242) Biosimilar rituximab...
BioCentury | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

...will run the clinical trial, its second independently run study. Sandi Wong and Hongjiang Li, Staff Writers AR201 biosimilar rituximab...
BioCentury | Aug 16, 2019
Product Development

China’s biosimilars in fast lane

Though coming from behind, China is cracking the seal on its biosimilar market and may even be poised to over-take the U.S. and Europe in less than a decade. On February 22, 2019, China’s National...
BioCentury | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

...IL-17A - Interleukin 17A; PDE-4 - Phosphodiesterase-4; S1P - Sphingosine-1 phosphate BC Staff Blitzima, Ritemvia, Truxima, Tuxella, biosimilar rituximab-abbs...
BioCentury | Feb 28, 2019
Clinical News

China approves first biosimilar, Shanghai Henlius’ HLX01

...Biotech Inc., Shanghai, China Henlius Biopharmaceuticals Co. Ltd., Shanghai, China Product: biosimilar rituximab (HLX01) Business: Cancer Hongjiang Li biosimilar rituximab...
BioCentury | Feb 25, 2019
Company News

China approves first biosimilar, Shanghai Henlius’ HLX01

...on the Hong Kong stock exchange ( "Shanghai Henlius up for Hong Kong IPO" ). Hongjiang Li biosimilar rituximab...
BioCentury | Dec 21, 2018
Financial News

Shanghai Henlius up for Hong Kong IPO

...Henlius Biopharmaceuticals Co. Ltd. (Shanghai, China), in Hong Kong. Shanghai Henlius Biotech Inc., Shanghai, China Chris Lieu biosimilar rituximab...
BioCentury | Dec 15, 2018
Financial News

Shanghai Henlius up for Hong Kong IPO

...Henlius, a JV between Fosun and Henlius Biopharmaceuticals Co. Ltd. (Shanghai, China), in Hong Kong. Chris Lieu biosimilar rituximab...
BioCentury | Nov 30, 2018
Clinical News

FDA approves first biosimilar for NHL

...Tel Aviv:TEVA), Petach Tikva, Israel Product: Truxima rituximab-abbs Business: Cancer Elizabeth S. Eaton Blitzima, Ritemvia, Truxima, Tuxella, biosimilar rituximab...
BioCentury | Nov 28, 2018
Company News

FDA approves first biosimilar for NHL

...PF-05280586, under FDA review with a PDUFA date in 3Q19. Elizabeth S. Eaton Blitzima, Ritemvia, Truxima, Tuxella, biosimilar rituximab...
Items per page:
1 - 10 of 59